Will take the CellPrime brand name
Merck Millipore, the life science division of Merck KGaA, has signed an exclusive agreement to sell recombinant human insulin manufactured by Julphar Diabetes of the United Arab Emirates.
The non-animal origin insulin will be marketed under Merck Millipore's CellPrime brand name, complementing the company's range of non-animal origin supplements for cell culture biomanufacturing.
Joe Saldanha, general manager of Julphar Diabetes, said: ‘This agreement marks a significant achievement for Julphar Diabetes and demonstrates the global impact that the state-of-the-art manufacturing facility is set to make on the diabetes drug industry worldwide. We are proud to be associated with such a strong partner in the life science sector.’
Merck Millipore says CellPrime insulin stimulates the proliferation of cells and aids in carbohydrate metabolism, helping to ensure the long-term viability of various cell lines. It also enhances cell growth rate and therapeutic protein production, while preventing morphological abnormalities of the cells.
Burghard Freiberg, senior vice president Pharm Chemicals Solutions at Merck Millipore, said: ‘Owing to its non-animal origin, its consistent manufacturing process and the traceability of its raw materials CellPrime enables manufacturers of monoclonal antibodies and recombinant biologics to use an insulin supplement that is both safe and effective.’
Julphar Diabetes manages the manufacturing and commercialisation of diabetes products. The firm’s manufacturing facility (Julphar XI) is built in accordance with the latest EMEA regulations.
The firm has extensive experience in the production of pharmaceutical grade materials, currently manufacturing more than 800 drugs with distribution in 40 countries.